Early urinary and plasma biomarkers for experimental diabetic nephropathy
- PMID: 22997966
Early urinary and plasma biomarkers for experimental diabetic nephropathy
Abstract
Background: As the prevalence of diabetes rises, its complications such as diabetic nephropathy affect an increaseing number of patients. Consequently, the need for biomarkers in rodent models which reflect the stage and course of diabetic nephropathy is high. This article focuses on Heart-type fatty acid binding protein (H-FABP), osteopontin (OPN), nephrin, and Neutrophil gelatinase-associated lipocalin (NGAL) in urine, and kidney injury molecule (KIM)-1, clusterin, and tissue inhibitior of metalloproteinases (TIMP) 1 in plasma in uni-nephrectomized rats with streptocotozin-induced type 1 diabetes mellitus, a common animal model to explore renal impairment in the setting of diabetes mellitus.
Methods: 23 male Wistar rats were uni-nephrectomized and subsequently divided into two study groups. The diabetic group received streptozotocin (STZ) via tail-vein injection, the non-diabetic group received citrate buffer without STZ. Subsequently, blood glucose, body weight, and blood pressure were checked regularly. After 18 weeks, animals were placed in metabolic cages, blood and urine obtained and subsequently organs were harvested after sacrifice.
Results: Blood glucose levels were highly increased in diabetic animals throughout the experiment, whereas systolic blood pressure did not differ between the study groups. At study end, classical biomarkers such as urinary albumin and protein and plasma cystatin c were only slightly but not significantly different between groups indicating a very early disease state. In contrast, urinary excretion of H-FABP, OPN, nephrin, and NGAL were highly increased in diabetic animals with a highly significant p-value (p < 0.01 each) compared to non-diabetic animals. In plasma, differences were found for calbindin, KIM-1, clusterin, TIMP-1, and OPN. These findings were confirmed by means of the area under the receiver operating characteristic curve (ROC-AUC) analysis.
Conclusions: In summary, our study revealed elevated levels of new plasma and urinary biomarkers (urinary osteopontin, urinary nephrin, urinary NGAL, urinary H-FABP, plasma KIM-1, plasma TIMP-1) in uni-nephrectomized diabetic rats, an established rat model of diabetic nephropathy. These biomarkers appeared even before the classical biomarkers of diabetic nephropathy such as albuminuria and urinary protein excretion. The new biomarkers might offer an advantage to urinary albumin and plasma cystatin c with respect to early detection.
Similar articles
-
Urinary cystatin C as a biomarker for diabetic nephropathy and its immunohistochemical localization in kidney in Zucker diabetic fatty (ZDF) rats.Exp Toxicol Pathol. 2013 Jul;65(5):615-22. doi: 10.1016/j.etp.2012.06.005. Epub 2012 Jul 12. Exp Toxicol Pathol. 2013. PMID: 22795897
-
Effects of benazepril on renal function and kidney expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in diabetic rats.Chin Med J (Engl). 2006 May 20;119(10):814-21. Chin Med J (Engl). 2006. PMID: 16732983
-
Combined therapy of rhein and benazepril on the treatment of diabetic nephropathy in db/db mice.Exp Clin Endocrinol Diabetes. 2007 Oct;115(9):571-6. doi: 10.1055/s-2007-981469. Exp Clin Endocrinol Diabetes. 2007. PMID: 17943690
-
[Clinical implication of urinary protein markers in diabetic nephropathy and interventional effects of Chinese herbal medicine].Zhongguo Zhong Yao Za Zhi. 2014 Jul;39(14):2589-94. Zhongguo Zhong Yao Za Zhi. 2014. PMID: 25272479 Review. Chinese.
-
Urinary liver type fatty acid binding protein in diabetic nephropathy.Clin Chim Acta. 2013 Sep 23;424:104-8. doi: 10.1016/j.cca.2013.05.020. Epub 2013 May 30. Clin Chim Acta. 2013. PMID: 23727660 Review.
Cited by
-
Biomarkers of diabetic kidney disease.Diabetologia. 2018 May;61(5):996-1011. doi: 10.1007/s00125-018-4567-5. Epub 2018 Mar 8. Diabetologia. 2018. PMID: 29520581 Free PMC article. Review.
-
Therapy with atorvastatin versus rosuvastatin reduces urinary podocytes, podocyte-associated molecules, and proximal tubule dysfunction biomarkers in patients with type 2 diabetes mellitus: a pilot study.Ren Fail. 2017 Nov;39(1):112-119. doi: 10.1080/0886022X.2016.1254657. Epub 2016 Nov 13. Ren Fail. 2017. PMID: 27841047 Free PMC article. Clinical Trial.
-
Urinary extracellular vesicles. A promising shortcut to novel biomarker discoveries.Cell Tissue Res. 2017 Jul;369(1):217-227. doi: 10.1007/s00441-017-2621-0. Epub 2017 Apr 20. Cell Tissue Res. 2017. PMID: 28429073 Free PMC article. Review.
-
Biomarkers of rapid chronic kidney disease progression in type 2 diabetes.Kidney Int. 2015 Oct;88(4):888-96. doi: 10.1038/ki.2015.199. Epub 2015 Jul 22. Kidney Int. 2015. PMID: 26200946
-
Effects of Mineralocorticoid Receptor Blockade and Statins on Kidney Injury Marker 1 (KIM-1) in Female Rats Receiving L-NAME and Angiotensin II.Int J Mol Sci. 2023 Mar 30;24(7):6500. doi: 10.3390/ijms24076500. Int J Mol Sci. 2023. PMID: 37047470 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials
Miscellaneous